Vitritis was the most common type of intraocular inflammation (IOI) seen in eyes treated with Intravitreal injections (IVI) of brolucizumab, according to a presentation at ARVO 2021.
In this retrospective study, researchers analyzed data from 88 patients (99 eyes) treated with intravitreal injections (IVI) of brolucizumab 6 mg/0.05 ml for neovascular age-related macular degeneration (NVAMD) over the course of 1 year. The majority of eyes (n = 89) were not treatment-naïve, and these patients experienced an average maintenance extension of 3 weeks. The average extension was 9 weeks for the 58 eyes (69.2%) that had a positive extension on maintenance. Of these 58 eyes, 24 had an injection burden reduction of ≥50% and were classified as super-responders.
Overall, IOI occurred in 8 eyes, all of which were diagnosed with vitritis, which lasted for 69 days on average. Retinal vasculitis occurred in 2 eyes with IOI, resulting in the loss of 3 letters and 10 letters, respectively. For the remaining 6 eyes without retinal vasculitis, the average vision change from IOI to the most recent visit was -2 letters, with 1 eye losing 10 letters of vision.
There was an average of 81 days from the first injection to the start of IOI, with reactions starting after 1-2 injection in the majority (n = 7) of eyes with IOI.
The researchers suggested that risk factors for IOI included atrial fibrillation and treatment-naivety.
Hamou S, et al. A retrospective study on the use of brolucizumab for the treatment of NVAMD: A 1-year private practice experience. Presented at: ARVO 2021.